SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Liquidia begins testing flu vaccine
News | 10. 06. 2010
Liquidia Technologies
Liquidia Technologies has started early clinical testing of its first vaccine developed using nanotechnology.
